格隆汇1月29日丨易明医药(002826.SZ)公布，预计2025年归属于上市公司股东的净利润7,400万元～ 10,200万元，比上年同期增长61.12%～122.08%，扣除非经常性损益后的净利润3,900万元～5,400万元， 比上年同期增长111.42%～192.74%。 报告期内，公司紧随行业发展方向及政策导向，集中资源大力发展自产产品，不断提升自产产品价值与 市场占有率，实现了核心自有产品米格列醇片的销量增长，带动整体利润提升，为公司的长期稳定发展 奠定基础。 ...

证券日报网讯1月29日，易明医药（002826）发布公告称，公司预计2025年度归属于上市公司股东的净 利润为7，400万元至10，200万元，比上年同期增长61.12%至122.08%。 ...

Group 1 - Meinian Health plans to participate in the restructuring of Zhejiang Bangjie Holdings, aiming to become the controlling shareholder after the completion of the restructuring [3] - Baiyin Nonferrous Metals reported that the revenue from gold and silver products accounted for a low proportion of total operating income, with gold sales contributing 18.67% and silver sales 4.54% in the first half of 2025 [4] - Tiens Wind Power decided to implement a long-term production suspension for six wholly-owned subsidiaries to optimize resource allocation and focus on core businesses [5] Group 2 - Tongling Nonferrous Metals indicated significant uncertainty in the price fluctuations of its main products, with a low self-sufficiency rate for copper concentrate posing supply stability risks [6] - *ST Aowei received a notice of termination of listing due to its market capitalization falling below 500 million yuan for twenty consecutive trading days [7] - Foton Motor expects a net profit increase of approximately 1551% year-on-year for 2025, driven by sales growth in new energy vehicles and overseas markets [9] Group 3 - Beimo High-tech anticipates a net profit increase of 1076.16% to 1261.87% for 2025, supported by cost control and reduced credit impairment losses [10] - Zhongke Sanhuan forecasts a net profit growth of 566.23% to 899.35% for 2025, attributed to technological innovation and improved operational efficiency [12] - Wancheng Group expects a net profit increase of 222.38% to 266.94% for 2025, driven by growth in its retail business and improved sales margins [13] Group 4 - Huayi Technology anticipates a net profit increase of 191.52% to 330.34% for 2025, benefiting from product optimization and cost reduction measures [14] - Nanmo Biology expects a net profit growth of 269.49% to 423.44% for 2025, supported by increased revenue in the biopharmaceutical sector and improved cost control [15] - Baiao Saitu forecasts a net profit increase of 384.26% to 443.88% for 2025, driven by expansion in overseas markets and recovery in the domestic biopharmaceutical industry [16] Group 5 - Hailanxin expects a net profit increase of 387.47% to 631.2% for 2025, supported by advancements in technology and increased market share in marine observation [17] - Panjiang Co. anticipates a net profit growth of 205.3% to 264.83% for 2025, driven by increased coal production and reduced costs [18] - Huaguang New Materials expects a net profit increase of 104.67% to 141.88% for 2025, with significant growth in the electronic sector [20] Group 6 - Guo Sheng Securities forecasts a net profit increase of 25.44% to 67.25% for 2025, supported by active capital market participation and growth in various business segments [25] - Shengyi Technology expects a net profit growth of 87% to 98% for 2025, driven by increased sales of copper-clad laminates [26] - Sifutian anticipates a net loss of 30 million to 45 million yuan for 2025, although this represents a significant reduction in losses compared to the previous year [27] Group 7 - Maanshan Steel expects a net loss of 1.9 billion to 2.5 billion yuan for 2025, with a substantial reduction in losses compared to the previous year [28] - Shennong Seed Industry forecasts a net profit of 90 million to 120 million yuan for 2025, marking a turnaround from previous losses [30] - Jifeng Co. anticipates a net profit of 410 million to 495 million yuan for 2025, achieving a turnaround from losses [31]

易明医药公告，预计2025年度净利润为7400万元到1.02亿元，同比增长61.12%～122.08%。报告期内， 公司紧随行业发展方向及政策导向，集中资源大力发展自产产品，不断提升自产产品价值与市场占有 率，实现了核心自有产品米格列醇片的销量增长，带动整体利润提升，为公司的长期稳定发展奠定基 础；非经常性损益主要来源于政府补助及博斯泰业绩承诺方补偿款等。预计非经常性损益对公司净利润 影响金额为4300万元。 ...

证券代码：002826 证券简称：易明医药 公告编号：2026-001 西藏易明西雅医药科技股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 | 项 | 目 | 本报告期 | | | | 上年同期 | | --- | --- | --- | --- | --- | --- | --- | | 归属于上市公司 | | | 7,400 | ～ | 10,200 | 4,592.88 | | 股东的净利润 | | 比上年同期增长 | 61.12% | ～ | 122.08% | | | 扣除非经常性损益 | | | 3,900 | ～ | 5,400 | 1,844.67 | | 后的净利润 | | 比上年同期增长 | 111.42% | ～ | 192.74% | | | 基本每股收益（元/股） | | | 0.40 | ～ | 0.56 | 0.25 | 二、与会计师事务所沟通情况 本次业绩预告相关数据是公司财务部门初步测算的结果，未经会计师事务所审计。但 公司已就业绩预告有关事项与年报审计会计师事务所进行了预沟通，公司与会计 ...

证券日报网讯1月22日，易明医药（002826）在互动平台回答投资者提问时表示，截至2026年1月20日， 本公司股东数为18392户。 ...

证券日报网讯 1月14日，易明医药在互动平台回答投资者提问时表示，截至2026年1月9日，公司股东数 为18668户。 （文章来源：证券日报） ...

Market Overview - The Shanghai Composite Index is at 4164.11 points, slightly above the five-day moving average, with a change of -0.03% [1] - The total trading volume of A-shares is 18505.22 billion yuan, with 228 A-shares breaking through the five-day moving average [1] Stocks with Significant Deviation - The stocks with the largest deviation from the five-day moving average include: - Dapeng Industrial (证券代: 920091) with a deviation of 8.06% and a price increase of 10.14% [1] - Hongxing Development (证券代: 600367) with a deviation of 7.42% and a price increase of 10.01% [1] - Prologis Pharmaceutical (证券代: 000739) with a deviation of 7.37% and a price increase of 10.03% [1] Additional Notable Stocks - Other notable stocks with significant price movements include: - Lek Electric (证券代: 603355) with a deviation of 7.20% and a price increase of 9.99% [1] - Tianyi Medical (证券代: 301097) with a deviation of 6.87% and a price increase of 11.59% [1] - Meihu Co., Ltd. (证券代: 603319) with a deviation of 6.30% and a price increase of 7.73% [1] Stocks with Smaller Deviations - Stocks that have just crossed the five-day moving average with smaller deviations include: - Cangge Mining (证券代: 300300) with a deviation of 3.83% and a price increase of 5.01% [1] - ST Xiangxue (证券代: 300147) with a deviation of 3.57% and a price increase of 4.79% [1] - Shandong Molong (证券代: 002490) with a deviation of 3.43% and a price increase of 5.62% [1]

证券日报网讯1月6日，易明医药（002826）在互动平台回答投资者提问时表示，截至2025年12月31日， 公司股东数为18111户。 ...

责任编辑：小浪快报 第2笔成交价格为18.07元，成交77.00万股，成交金额1,391.39万元，溢价率为-1.69%，买方营业部为中 国中金财富证券有限公司上海黄浦区湖滨路证券营业部，卖方营业部为西南证券股份有限公司湖南分公 司。 进一步统计，近3个月内该股累计发生2笔大宗交易，合计成交金额为3035.76万元。该股近5个交易日累 计上涨1.94%，主力资金合计净流出566.03万元。 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 12月31日，易明医药收涨1.72%，收盘价为18.38元，发生2笔大宗交易，合计成交量168万股，成交金额 3035.76万元。 第1笔成交价格为18.07元，成交91.00万股，成交金额1,644.37万元，溢价率为-1.69%，买方营业部为华 林证券股份有限公司深圳分公司，卖方营业部为西南证券股份有限公司湖南分公司。 ...